Xvivo Perfusion AB (XVIVO):企業の財務・戦略的SWOT分析

◆英語タイトル:Xvivo Perfusion AB (XVIVO) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME290181FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xvivo Perfusion AB (Xvivo) is a medical technology company that provides organ transplantation solutions. The company develops organ preservation products such as perfadex and silicone tubing sets and normothermic perfusion products. It offers normothermic perfusion products such as STEEN solutions, XVIVO organ chambers, XVIVO lung cannula sets and XPS-XVIVO perfusion systems, among others. Xvivo develops its products based on ex vivo lung perfusion technology. The company markets its products in Italy, Sweden, Turkey, Israel, India, Japan, the US and Brazil. Xvivo is headquartered in Gothenburg, Sweden.

Xvivo Perfusion AB Key Recent Developments

Feb 17,2021: First Belgian patient receives heart transplant with new preservation technology
Jul 10,2020: XVIVO Perfusion : In the starting blocks for heart preservation and PrimECC trial
Apr 28,2020: Magnus Nilsson hands over the baton to Dag Andersson as President and CEO of XVIVO Perfusion
Apr 09,2020: Strong cash flow despite the influence of Covid-19
Jan 30,2020: Xvivo Perfusion: A historic year ended with a quarter of sales records

This comprehensive SWOT profile of Xvivo Perfusion AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Xvivo Perfusion AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Xvivo Perfusion AB – Key Information
Xvivo Perfusion AB – Overview
Xvivo Perfusion AB – Key Employees
Xvivo Perfusion AB – Key Employee Biographies
Xvivo Perfusion AB – Key Operational Heads
Xvivo Perfusion AB – Major Products and Services
Xvivo Perfusion AB – History
Xvivo Perfusion AB – Company Statement
Xvivo Perfusion AB – Locations And Subsidiaries
Xvivo Perfusion AB
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Xvivo Perfusion AB – Business Description
Xvivo Perfusion AB – Corporate Strategy
Xvivo Perfusion AB – SWOT Analysis
SWOT Analysis – Overview
Xvivo Perfusion AB – Strengths
Xvivo Perfusion AB – Weaknesses
Xvivo Perfusion AB – Opportunities
Xvivo Perfusion AB – Threats
Xvivo Perfusion AB – Key Competitors

Section 3 – Company Financial Performance Charts

Xvivo Perfusion AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Xvivo Perfusion AB, Key Information
Xvivo Perfusion AB, Key Ratios
Xvivo Perfusion AB, Share Data
Xvivo Perfusion AB, Major Products and Services
Xvivo Perfusion AB, History
Xvivo Perfusion AB, Key Employees
Xvivo Perfusion AB, Key Employee Biographies
Xvivo Perfusion AB, Key Operational Heads
Xvivo Perfusion AB, Other Locations
Xvivo Perfusion AB, Subsidiaries
Xvivo Perfusion AB, Key Competitors
Xvivo Perfusion AB, SWOT Analysis
Xvivo Perfusion AB, Ratios based on current share price
Xvivo Perfusion AB, Annual Ratios
Xvivo Perfusion AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Xvivo Perfusion AB (XVIVO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …
  • InterDigital Inc (IDCC):企業の財務・戦略的SWOT分析
    InterDigital Inc (IDCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • HDI-Global SE:企業の戦略・SWOT・財務分析
    HDI-Global SE - Strategy, SWOT and Corporate Finance Report Summary HDI-Global SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • BAB, Inc.:企業の戦略・SWOT・財務情報
    BAB, Inc. - Strategy, SWOT and Corporate Finance Report Summary BAB, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Hsh Nordbank Private Banking
    Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Protea Biosciences Group Inc (PRGB):企業の財務・戦略的SWOT分析
    Summary Protea Biosciences Group Inc (Protea) operates as a biotechnology company that develops mass spectometry solutions. The company offers technology for identification, characterization, and quantitation of biologically-important molecules for pharmaceutical development, research, and diagnosti …
  • Teladoc Health Inc (TDOC):医療機器:M&Aディール及び事業提携情報
    Summary TelaDoc Health Inc (Teladoc Health) is a provider of telehealth services. The company offers short term prescription for amoxicillin, azithromycin, bactrim DS, augmentin, cipro, tessalon perles, flonase nasal spray, pyridium, prednisone and diflucan. It provides telehealth services for cold …
  • ELITechGroup Inc:企業の製品パイプライン分析2018
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cystic fibrosis, hematology, microbiology and molecular diagnostics. Its clinical chemistry produ …
  • Moberg Pharma AB (MOB):医療機器:M&Aディール及び事業提携情報
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • DMC Global Inc (BOOM):企業の財務・戦略的SWOT分析
    Summary DMC Global Inc (DMC), formerly Dynamic Materials Corp is an industrial equipment and machinery company. It manufactures, distributes, and markets explosion welded clad metal plates. The company’s products include oilfield products, explosive metalworking equipment, and AMK welding equipment, …
  • Kadmon Holdings Inc (KDMN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadmon Holdings Inc (Kadmon) is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for th …
  • Dicerna Pharmaceuticals Inc (DRNA)-製薬・医療分野:企業M&A・提携分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies.The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. Its pipeline product is being generated from the company’s propri …
  • Constellation Brands Inc (STZ):企業の財務・戦略的SWOT分析
    Constellation Brands Inc (STZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Blackstone Group LP:戦略・SWOT・企業財務分析
    The Blackstone Group LP - Strategy, SWOT and Corporate Finance Report Summary The Blackstone Group LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BM-Bank Public Joint Stock Company:企業のM&A・事業提携・投資動向
    BM-Bank Public Joint Stock Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BM-Bank Public Joint Stock Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Saudi Kayan Petrochemical Co (2350):企業の財務・戦略的SWOT分析
    Summary Saudi Kayan Petrochemical Co (Saudi Kayan) is a petrochemical company that manufactures and markets specialty chemicals. The company offers products such as ethanolamines, ethoxylates, phenol, cumene, polycarbonate, ethylene, propylene, polyethylene, monoethanolamine, diethanolamine, trietha …
  • Biofrontera AG (B8F):企業の財務・戦略的SWOT分析
    Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Enterprise Products Partners LP (EPD):石油・ガス:M&Aディール及び事業提携情報
    Summary Enterprise Products Partners LP (Enterprise Products) is a provider of midstream energy services. The company‘s services include natural gas gathering, treating, processing, transportation and storage; transportation of natural gas liquids (NGL), fractionation, storage, and import and export …
  • ANI Pharmaceuticals Inc (ANIP):製薬・医療:M&Aディール及び事業提携情報
    Summary ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company’s product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheuma …
  • DURECT Corp (DRRX):企業の財務・戦略的SWOT分析
    DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆